etoposide has been researched along with tafluposide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barret, JM; Etiévant, C; Hill, BT; Imbert, T; Kruczynski, A; Perrin, D; van Hille, B | 1 |
| Barret, JM; Etiévant, C; Guminski, Y; Hill, BT; Kruczynski, A; Perrin, D; van Hille, B | 1 |
| Barret, JM; Hill, BT; Olive, PL | 1 |
| Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A; van Hille, B | 1 |
| Astruc, J; Barret, JM; Chansard, N; Créancier, L; Duchier, C; Hill, BT; Kruczynski, A; Menon, Y; Van Hille, B | 1 |
| Bailly, C; Hartley, JA; Irwin, H; Kluza, J; Mazinghien, R | 1 |
6 other study(ies) available for etoposide and tafluposide
| Article | Year |
|---|---|
F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Cattle; Cell Nucleus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Enzyme Stability; Etoposide; Evaluation Studies as Topic; Humans; Naphthalenes; Pyrans; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Topics: Aclarubicin; Aminoquinolines; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Etoposide; Humans; Indenes; Indoles; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Pyrans; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases.
Topics: Animals; Camptothecin; Cell Line; Comet Assay; DNA; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Etoposide; Naphthalenes; Pyrans; Spheroids, Cellular; Time Factors; Topoisomerase I Inhibitors | 2000 |
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Neoplasm Transplantation; Piperazines; Pyrans; Razoxane; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Northern; Catalysis; Cell Line, Tumor; Cisplatin; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Leukemia; Mice; Mice, Inbred DBA; Mutation, Missense; Naphthalenes; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Pyrans; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2004 |
Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; DNA, Neoplasm; Etoposide; HL-60 Cells; Humans; Naphthalenes; Pyrans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2006 |